Aunque la causa más común de embolia coronaria es la fibrilación auricular, no debemos olvidar que existen otras afecciones que, a pesar de su baja frecuencia, se deben descartar para establecer un ...tratamiento definitivo. Entre ellas se encuentran las malformaciones arteriovenosas, como en el caso que se presenta a continuación. Una mujer de 36 años, con un síndrome de Rendu-Osler-Weber con epistaxis espontáneas recurrentes como único antecedente personal, acudió a urgencias por dolor centrotorácico opresivo, irradiado al miembro superior izquierdo y la espalda, acompañado de cortejo vegetativo. En el electrocardiograma se apreció una lesión subepicárdica en V2-3 que asociaba cifras de troponina ultrasensible con un pico máximo de 9.148 pg/ml.
Chronic inhibition of the renin angiotensin system prevents increased BP and renal injury in N(G)-nitro-L-arginine methyl ester (L-NAME) hypertension. However, a relationship between plasma renin ...activity and the protective effect of chronic angiotensin II (Ang II) blockade has not been established. With this background, this study was undertaken to evaluate how the chronic administration of deoxycortisone acetate (DOCA) modifies the effects of losartan on BP, renal injury, and other variables in L-NAME hypertensive rats. The following groups were used: Control, DOCA, L-NAME, L-NAME + losartan, L-NAME + DOCA, and L-NAME + DOCA + losartan. Tail systolic BP was measured twice a week. After 4-wk evolution, mean arterial pressure and metabolic, morphologic, and renal variables were measured. The final mean arterial pressure values were 116 +/- 6 mmHg for control, 107 +/- 2 mmHg for DOCA, 151 +/- 5 mmHg for L-NAME, 123 +/- 2 mmHg for L-NAME + losartan, 170 +/- 3 mmHg for L-NAME + DOCA, and 171 +/- 5.5 mmHg for L-NAME + DOCA + losartan. Losartan prevented microalbuminuria, hyaline arteriopathy, and glomerulosclerosis of L-NAME hypertension but was ineffective in L-NAME + DOCA-treated rats. Plasma protein was significantly reduced in the L-NAME + DOCA group when compared with control and L-NAME groups, whereas no significant differences were observed in the other groups. Plasma renin activity was suppressed in the DOCA (0.55 +/- 0.2) and L-NAME + DOCA (0.60 +/- 10.2) groups but unsuppressed in the L-NAME + DOCA + losartan group (5.8 +/- 1). The conclusion is that DOCA blocks the preventive effect of losartan on the increased BP and renal injury of L-NAME hypertension, which suggests that DOCA transforms L-NAME hypertension into an Ang II-independent model of hypertension. These data also suggest that losartan prevents L-NAME hypertension by blocking the activity of systemic Ang II.
This study investigates the effects of chronic administration of omapatrilat (OMA) on blood pressure (BP), renal injury, and other variables in Nω-nitro-l-arginine methyl ester (L-NAME) hypertension ...and in the low-renin model produced by the simultaneous administration of L-NAME and deoxycorticosterone acetate (DOCA).
The control, DOCA, L-NAME, L-NAME + DOCA, L-NAME + OMA, and L-NAME + DOCA + OMA groups were used. Tail systolic BP was measured twice a week. After 4 weeks of treatment, mean arterial pressure (MAP), and metabolic, morphologic, and renal variables were measured.
The final values of MAP were 109 ± 5.1 mm Hg for the control group, 113 ± 3.0 mm Hg for DOCA, 175 ± 3.7 mm Hg for L-NAME, 193 ± 3.8 mm Hg for L-NAME + DOCA, 117 ± 3.9 mm Hg for L-NAME + OMA, and 158 ± 3.0 mm Hg for L-NAME + DOCA + OMA. The rats treated with L-NAME showed mild and scarce renal lesions, which were prevented by OMA treatment and the L-NAME + DOCA group showed proteinuria and hyaline arteriopathy, which were markedly attenuated in the L-NAME + DOCA + OMA group. Plasma urea and creatinine were significantly increased in the L-NAME + DOCA group, whereas these variables were not significantly greater in the L-NAME + DOCA + OMA group versus controls. The L-NAME + DOCA group showed relative renal and cardiac hypertrophy that was not observed in the L-NAME + DOCA + OMA group.
The simultaneous blockade of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) completely prevents L-NAME hypertension. Our results also show that OMA attenuates the increased BP and the renal injury in L-NAME hypertensive rats treated with DOCA. Assuming that this is a low-renin model of hypertension, the protective effect of OMA may be due to an increase in vasodilator peptides produced by both ACE and NEP inhibition.
P-glycoprotein (P-gp) expels hydrophobic substances from the cell, including chemotherapeutic agents and immunosuppressants such as cyclosporin A (CsA) and FK506. Exposure of cultured renal tubular ...cells to CsA induces P-gp overexpression in cell membranes. Angiotensin II has recently been implicated as the principal factor responsible for progression of interstitial fibrosis induced by CsA. To investigate the in vivo relationships between histological lesions, P-gp overexpression, and intrarenal angiotensin II deposits, we developed a model of chronic CsA toxicity in Sprague-Dawley rats treated with 25 mg/kg/day CsA for 28 and 56 days and fed either a standard maintenance diet or a low-salt diet. Immunohistochemical methods were used to study the expression of P-gp in renal tubular cells and the appearance of intrarenal angiotensin II deposits. Rats treated with CsA developed chronic nephrotoxicity lesions that were more evident in the group fed the low-salt diet. Treatment with CsA induced overexpression of P-gp in tubular cells of the kidney that increased with time. We found that immunohistochemical expression of P-gp was slightly more severe in rats fed a low-salt diet. Intrarenal deposits of angiotensin II were more evident in rats treated with CsA; these deposits also increased with time. This finding was also more relevant in rats given the low-salt diet. The up-regulation of P-gp was inversely related to the incidence of hyaline arteriopathy (r = -0.65; P < 0.05), periglomerular (r = -0.58; P < 0.05) and peritubular fibrosis (r = -0.63; P < 0.05), and intrarenal angiotensin H deposits in animals with severe signs of nephrotoxicity (r = -0.65; P < 0.05). These results support the hypothesis that the role of P-gp as a detoxicant in renal cells may be related to mechanisms that control the cytoplasmic removal of both toxic metabolites from CsA and those originating from the catabolism of signal transduction proteins (methylcysteine esters), which are produced as a result of ras activation in presence of angiotensin II.
Mesial temporal lobe epilepsy with hippocampal sclerosis is the most common cause of refractory epilepsy, and the most common indication for surgery. Although effective, surgery fails in up to 40% of ...patients. The objective of our study was to establish a correlation between the different histological subtypes of mesial temporal lobe epilepsy with hippocampal sclerosis and the prognosis, seizures control, side effects and anticonvulsivant drug withdrawal in patients with refractory epilepsy.
Clinical histories and anatomopathological specimens of 228 patients with temporal epilepsy surgically obtained at our hospital between 1993 and 2014 were retrospectively analyzed. All patients underwent a standard preoperative evaluation and anterior temporal resection (modified from Spencer). The anatomopathological study included the standard hematoxylin–eosin and immunohistochemical protocol, with special interest in the assessment of neuronal loss with NeuN. Seizure control was assessed according to the scale of results of the ILAE and Engel. The mean follow-up was 8.6 years (2–19).
At 10 years after the intervention, 67.9% of patients were seizure-free (ILAE 1) and as many as 77.5% of the patients were seizure-free (Engel 1) at the end of the follow-up. The probability of not having a seizure (ILAE 1) after surgery at 2 (p=0.042), 5 (p=0.001) and 7 years (p=0.22) was higher in classic and severe forms compared to isolated sclerosis CA1 and CA4 forms. Higher neuronal loss measured with the NeuN immunostain in CA1 was associated with better outcome in seizure management (multivariate analysis, p=0.08). The presence of a personal history of epilepsy was associated with greater neuronal loss in CA1 (p=0.028) and CA3 (p=0.034), and the presence of psychic auras was related with greater neuronal loss in CA3 (p=0.025). In our case, the probability of medication withdrawal was related to the presence of personal history (p=0.003) and, inversely, to neuronal loss in CA1 (p=0.036) and CA3 (p=0.038). The greatest impairment of verbal memory occurred in those patients with a lower neuronal loss in CA1 (p=0.023), CA2 (p=0.049) and CA3 (p=0.035).
The results indicate that the classical and severe subtypes have a better prognosis in the control of seizures against the atypical forms, validating the clinical and prognostic utility of the classification of histological subtypes of hippocampal sclerosis from the ILAE. The value of the immunohistochemistry in the mesial temporal lobe epilepsy with hippocampal sclerosis has been demonstrated as a key element to determine the neuropsychological prognosis and seizure management of the patients after surgery.
La epilepsia temporal con esclerosis hipocampal es la causa más frecuente de epilepsia refractaria, y la indicación más común de cirugía. Aunque eficaz, la cirugía fracasa hasta en un 40% de los pacientes. El objetivo de nuestro trabajo es establecer una correlación entre los distintos subtipos histológicos de epilepsia temporal con esclerosis hipocampal y el pronóstico, control de crisis, efectos secundarios y retirada de fármacos anticomiciales en los pacientes con epilepsia resistente a fármacos intervenidos.
Se analizaron de forma retrospectiva las historias clínicas y muestras anatomopatológicas de 228 pacientes con epilepsia temporal intervenidos en nuestro centro entre los años 1993 y 2014. Todos fueron sometidos a una evaluación prequirúrgica estándar e intervenidos mediante una resección temporal anterior (modificada de Spencer). El estudio anatomopatológico incluyó el protocolo de hematoxilina-eosina e inmunohistoquímico estándar, con especial interés en la valoración de pérdida neuronal con NeuN. El control de las crisis fue valorado de acuerdo a la escala de resultados de la ILAE y de Engel. El seguimiento medio fue de 8,6 años (2-19).
A los 10 años tras la intervención, un 67,9% de los pacientes se encontraban libres de crisis (ILAE 1). Un 77,5% de los pacientes estaba libre de crisis (Engel 1) al final del seguimiento. La probabilidad de quedar sin crisis (ILAE 1) tras la cirugía a los 2 (p=0,042), 5 (p=0,001) y 7 (p=0,022) años fue mayor en las formas clásica y severa frente a las formas de esclerosis aislada CA1 y CA4. Una mayor pérdida neuronal medida con NeuN en CA1 se relacionó con un mejor resultado en el control de las crisis (análisis multivariante, p=0,08). La presencia de antecedentes personales desencadenantes de epilepsia se relacionó con una mayor pérdida neuronal en CA1 (p=0,028) y CA3 (p=0,034), y la presencia de auras psíquicas con una mayor pérdida de neuronas en CA3 (p=0,025). En nuestro caso, la probabilidad de dejar la medicación se relacionó con la presencia de antecedentes personales (p=0,003) y, de forma inversa, con la pérdida neuronal en CA1 (p=0,036) y CA3 (p=0,038). El mayor deterioro de memoria verbal ocurrió en aquellos pacientes con menor pérdida neuronal en CA1 (p=0,023), CA2 (p=0,049) y CA3 (p=0,035).
Los resultados señalan que los subtipos clásico y severo tienen un mejor pronóstico en el control de las crisis frente a las formas atípicas, validándose la utilidad clínica y pronóstica de la clasificación de consenso de los subtipos histológicos de esclerosis hipocampal de la ILAE. Se ha demostrado el valor de la inmunohistoquímica en la epilepsia temporal con esclerosis hipocampal como un elemento clave para determinar el pronóstico en el control de las crisis y neuropsicológico de los pacientes tras la cirugía.